MedPath

Effect of topical recombinant human epidermal growth factor on chronic diabetic ulcer compared with conventional saline dressing

Phase 3
Conditions
Health Condition 1: - Health Condition 2: E119- Type 2 diabetes mellitus without complications
Registration Number
CTRI/2024/05/067239
Lead Sponsor
Dr A Sneha Daffodil
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Grade 1 and 2 wagners classification

ulcer duration more than 3 weeks

able to understand the merits and demerits of both the procedure and provide consent

Exclusion Criteria

Age less than 18 years and more than 80 years 2.Patient with cardiac disease,HIV,Hepatitis, pregnancy and critically ill patients 3.Chronic venous/Aretrial ulcers 4.Malignant ulcers 5.Anemia( <7gm/dl) 6.Known or Suspected osteomyelitis 7.Ulcer is less than 2cm.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath